// App-Quantinova.ai

: Mesoglycan vs Placebo in Secondary Prevention of Superficial Vein Thrombosis. Rationale and Protocol

Researchers

Presenter

  • G. Camporese

Principal Investigators

  • E. Bernardi

  • C. Bortoluzzi

  • G. Avruscio

  • F. Noventa

Medical Centers

  • University Hospital of Padua ‐ Unit of Angiology, Cardiac, Thoracic and Vascular Sciences, Padua, Italy

  • Civic Hospital of Conegliano, Emergency and accident Medicine, Conegliano, Italy

  • Civic Hospital of Venice, Internal Medicine, Venice, Italy

  • University Hospital of Padua, Laboratory Medicine, Padua, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Angiology

Disease

  • Superficial Vein Thrombosis

  • Venous thrombosis

  • Deep vein thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Fondaparinux sodium

  • Mesoglycan

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved